Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 13/20 | 0.47 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.46 |
| ▸ | DRD2 | P14416 | 2/20 | 0.38 |
| ▸ | DRD3 | P35462 | 2/20 | 0.38 |
| ▸ | OGA | O60502 | 2/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.36 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | HTR1D | P28221 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2010406 | 0.94 | HRH4 (0.45) | HRH4CXCR4DRD2DRD3OGA | |
| SCHEMBL2014636 | 0.94 | HRH4 (0.45) | HRH4CXCR4DRD2DRD3OGA | |
| SCHEMBL2010314 | 0.94 | HRH4 (0.45) | HRH4CXCR4DRD2DRD3OGA | |
| SCHEMBL4105627 | 0.94 | HRH4 (0.45) | HRH4CXCR4DRD2DRD3OGA | |
| SCHEMBL4103950 | 0.94 | HRH4 (0.45) | HRH4CXCR4DRD2DRD3OGA | |
| SCHEMBL4108575 | 0.94 | HRH4 (0.45) | HRH4CXCR4DRD2DRD3OGA | |
| SCHEMBL229092 | 0.89 | CXCR4 (0.53) | HRH4CXCR4MAPK8HRH3 | |
| SCHEMBL229091 | 0.89 | CXCR4 (0.53) | HRH4CXCR4MAPK8HRH3 | |
| SCHEMBL4110612 | 0.89 | HRH4 (0.52) | HRH4CXCR4DRD2DRD3OGA | |
| SCHEMBL4116679 | 0.89 | CXCR4 (0.42) | HRH4CXCR4DRD2DRD3OGA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233908-A1 | NITROGENOUS HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233908-A1 | NITROGENOUS HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF | CXCR4, CXCR1, CXCL12 | HRH4 152/4885CXCR4 1/4885DRD2 2501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.